CLINICAL TRIALS PROFILE FOR IDARUBICIN HYDROCHLORIDE PFS
✉ Email this page to a colleague
All Clinical Trials for Idarubicin Hydrochloride Pfs
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002517 ↗ | Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 | 1993-03-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for acute myeloid leukemia or myelodysplastic syndrome. PURPOSE: Randomized phase III trial to compare the effectiveness of different combination chemotherapy regimens in treating children who have newly diagnosed acute myeloid leukemia or myelodysplastic syndrome. |
| NCT00002532 ↗ | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia | Unknown status | Hannover Medical School | Phase 2 | 1993-01-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have relapsed or refractory acute lymphocytic leukemia. |
| NCT00002549 ↗ | Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia | Unknown status | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 | 1993-11-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy followed by bone marrow or peripheral stem cell transplantation in treating patients with acute myelogenous leukemia. |
| NCT00002565 ↗ | Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma | Completed | National Cancer Institute (NCI) | Phase 3 | 1994-05-25 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective for intermediate-grade or immunoblastic non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have intermediate-grade or immunoblastic non-Hodgkin's lymphoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Idarubicin Hydrochloride Pfs
Condition Name
Clinical Trial Locations for Idarubicin Hydrochloride Pfs
Trials by Country
Clinical Trial Progress for Idarubicin Hydrochloride Pfs
Clinical Trial Phase
Clinical Trial Sponsors for Idarubicin Hydrochloride Pfs
Sponsor Name
